These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30531837)

  • 21. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
    Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
    Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
    Wang N; Wen J; Ren W; Wu Y; Deng C
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.
    Schweppe RE; Kerege AA; French JD; Sharma V; Grzywa RL; Haugen BR
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2199-203. PubMed ID: 19293266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
    Chan CM; Jing X; Pike LA; Zhou Q; Lim DJ; Sams SB; Lund GS; Sharma V; Haugen BR; Schweppe RE
    Clin Cancer Res; 2012 Jul; 18(13):3580-91. PubMed ID: 22586301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Focal adhesion targeting of v-Crk is essential for FAK phosphorylation and cell migration in mouse embryo fibroblasts deficient src family kinases or p130CAS.
    Yeo MG; Sung BH; Oh HJ; Park ZY; Marcantonio EE; Song WK
    J Cell Physiol; 2008 Mar; 214(3):604-13. PubMed ID: 17786957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
    Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
    Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC
    Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective involvement of p130Cas/Crk/Pyk2/c-Src in endothelin-1-induced JNK activation.
    Kodama H; Fukuda K; Takahashi E; Tahara S; Tomita Y; Ieda M; Kimura K; Owada KM; Vuori K; Ogawa S
    Hypertension; 2003 Jun; 41(6):1372-9. PubMed ID: 12719447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.
    Vanden Borre P; Gunda V; McFadden DG; Sadow PM; Varmeh S; Bernasconi M; Parangi S
    Oncotarget; 2014 Jun; 5(12):3996-4010. PubMed ID: 24994118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.
    Chang AY; Wang M
    BMC Cancer; 2013 May; 13():267. PubMed ID: 23721490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).
    Xing J; Liu R; Xing M; Trink B
    Biochem Biophys Res Commun; 2011 Jan; 404(4):958-62. PubMed ID: 21185263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
    Wu ZH; Lin C; Liu MM; Zhang J; Tao ZH; Hu XC
    PLoS One; 2016; 11(12):e0169230. PubMed ID: 28036386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
    Leboeuf R; Baumgartner JE; Benezra M; Malaguarnera R; Solit D; Pratilas CA; Rosen N; Knauf JA; Fagin JA
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2194-201. PubMed ID: 18381570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/mitogen-activated protein kinase: summation of both c-Src- and focal adhesion kinase-initiated tyrosine phosphorylation events.
    Schlaepfer DD; Jones KC; Hunter T
    Mol Cell Biol; 1998 May; 18(5):2571-85. PubMed ID: 9566877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paradoxical activation of c-Src as a drug-resistant mechanism.
    Higuchi M; Ishiyama K; Maruoka M; Kanamori R; Takaori-Kondo A; Watanabe N
    Cell Rep; 2021 Mar; 34(12):108876. PubMed ID: 33761359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential regulation of cell motility and invasion by FAK.
    Hsia DA; Mitra SK; Hauck CR; Streblow DN; Nelson JA; Ilic D; Huang S; Li E; Nemerow GR; Leng J; Spencer KS; Cheresh DA; Schlaepfer DD
    J Cell Biol; 2003 Mar; 160(5):753-67. PubMed ID: 12615911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
    PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
    Vultur A; Buettner R; Kowolik C; Liang W; Smith D; Boschelli F; Jove R
    Mol Cancer Ther; 2008 May; 7(5):1185-94. PubMed ID: 18483306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.